Comparing modes of delivery of a combination of ion channel inhibitors for limiting secondary degeneration following partial optic nerve transection

Sci Rep. 2019 Oct 25;9(1):15297. doi: 10.1038/s41598-019-51886-3.

Abstract

Injury to the central nervous system is exacerbated by secondary degeneration. Previous research has shown that a combination of orally and locally administered ion channel inhibitors following partial optic nerve injury protects the myelin sheath and preserves function in the ventral optic nerve, vulnerable to secondary degeneration. However, local administration is often not clinically appropriate. This study aimed to compare the efficacy of systemic and local delivery of the ion channel inhibitor combination of lomerizine, brilliant blue G (BBG) and YM872, which inhibits voltage-gated calcium channels, P2X7 receptors and Ca2+ permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors respectively. Following a partial optic nerve transection, adult female PVG rats were treated with BBG and YM872 delivered via osmotic mini pump directly to the injury site, or via intraperitoneal injection, both alongside oral administration of lomerizine. Myelin structure was preserved with both delivery modes of the ion channel inhibitor combination. However, there was no effect of treatment on inflammation, either peripherally or at the injury site, or on the density of oligodendroglial cells. Taken together, the data indicate that even at lower concentrations, the combinatorial treatment may be preserving myelin structure, and that systemic and local delivery are comparable at improving outcomes following neurotrauma.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcium Channel Blockers / administration & dosage
  • Calcium Channels / metabolism
  • Drug Therapy, Combination
  • Female
  • Imidazoles / administration & dosage*
  • Myelin Sheath / drug effects*
  • Myelin Sheath / metabolism
  • Nerve Degeneration / etiology
  • Nerve Degeneration / prevention & control*
  • Optic Nerve / surgery
  • Optic Nerve Injuries / complications*
  • Piperazines / administration & dosage*
  • Quinoxalines / administration & dosage*
  • Rats
  • Receptors, AMPA / antagonists & inhibitors
  • Receptors, AMPA / metabolism
  • Receptors, Purinergic P2X7 / metabolism
  • Rosaniline Dyes / administration & dosage*

Substances

  • Calcium Channel Blockers
  • Calcium Channels
  • Imidazoles
  • Piperazines
  • Quinoxalines
  • Receptors, AMPA
  • Receptors, Purinergic P2X7
  • Rosaniline Dyes
  • YM 872
  • lomerizine
  • coomassie Brilliant Blue